Skip Navigation
Search Menu
Heart & Vascular Institute

In This Section      
Print This Page

Takimoto Lab Publications

Selected Publications:

  1. Takimoto E, Soergel DG, Janssen PML, Stull LB, Kass DA, Murphy AM. Frequency-and afterload dependent cardiac modulation in vivo by troponin I with constitutively active protein kinase A phosphorylation sites. Circ Res 2004; 94; 496-504.

  2. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Megia E, Montrose DC, Isoda T, Aufiero K, Zaccolo M, Dostmann WRG, Smith CJ, Kass DA. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 2005; 96: 100-109.

  3. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11: 214-222.

  4. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, Lazzarino G, Paolocci N, Gabrielson KL, Wang Y, Kass DA. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure-load. J Clin Invest 2005; 115: 1221-1231.

  5. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling.   Hypertension 2007; 49: 241-8.

  6. Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Ketner EA, Moens AL, Champion HC, Kass DA. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation 2007; 96: 100-109.

  7. Kass DA, Takimoto E, Nagayama T, Champion HC. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc Res 2007; 49: 241-8.

  8. Nagayama T, Takimoto E, Sadayappan S, Mudd JO, Seidman JG, Robbins J, Kass DA. PKA-phosphorylation dependent and independent regulation of in vivo contraction /relaxation kinetics by myosin binding protein C. Circulation 2007; 116: 2399-408.

  9. Nagayama T, Zhang M, Hsu S, Takimoto E, Kass DA. Sustained soluble guanylate cyclase stimulation offsets NOS inhibition to restore acute cardiac modulation by sildenafil. J Pharmacol Exp Ther 2008; 326: 380-387.

  10. Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G, Ketner EA, Majmudar M, Gabrielson KL, Halushka MK, Michell JB, Biswal S, Channon KM, Wolin MS, Alp, NJ, Paolocci N, Champion HC, Kass DA. Reversal of cardiac hypertrophy and fibrosis from pressure-overload by tetrahydrobiopterin: Efficacy of re-coupling of nitric oxide synthase as a therapeutic strategy. Circulation 2008; 117: 2626-2636.

  11. Zhang M, Koitabashi N, Nagayama T, Rambaran R, Feng N, Takimoto E, Koenke T, O’Rourke B, Champion HC, Crow MT, Kass DA. Expression, activity and pro-hypertrophic effect of PDE5A in cardiac myocytes. Cell Signal 2008; 20: 2231-6.

  12. Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL, Takimoto E, Kass DA. Sildenafil stops progression of chamber, cellular and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy due to pressure-overload. J Am Coll Cardiol 2009; 53: 207-215.

  13. Hsu S, Nagayama T, Koitabashi N, Zhang M, Zhou L, Bedja D, Gabrielson KL, Molkentin JD, Kass DA, Takimoto E*. Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. Cardiovasc Res 2009; 81: 301-9.

  14. Takimoto E*, Koitabashi N, Hsu S, Ketner EA, Zhang M, Nagayama T, Bedja D, Gabrielson KL, Blanton R, Siderovski DP, Mendelsohn ME, Kass DA. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest 2009; 119: 408-20.

  15. Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL, Takimoto E, Kass DA. Pressure-overload magnitude-dependence of anti-hypertrophic effects from PDE5 inhibition. J Mol Cell Cardiol 2009; 46: 560-567.

  16. Koitabashi N, Bedja D, Zaiman AL, Pinto YM, Zhang M, Gabrielson KL, Takimoto E, Kass DA. Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circ Res 2009; 105: 12-5.

  17. Takimoto E*. Controlling myocte cGMP – PDE1 joins the fray (In Press). Circ Res 2009; November 6.